| NCT ID | NCT06929923 |
| Status | Recruiting |
| Phase | — |
| Sponsor | TecTraum Inc. |
| Condition | Concussion, Mild |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2025-02-20 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2025-02-20 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being conducted to determine the clinical safety and efficacy of Pro-2-Cool mediated head and neck cooling when applied after concussion and improved symptomatology among adolescent athletes as quantified by post-concussion symptom severity (PCSS) score.
Eligibility Criteria
Inclusion Criteria: 1. Males and females, 13-21 years of age 2. Confirmed concussion diagnosis consistent with American Congress Rehabilitation Medicine guidelines 21, without any of the following: * Glasgow Coma Scale (GCS) score of less than 13 at 30 minutes post-injury * Loss of consciousness greater than 30 minutes * Post-traumatic amnesia lasting over 24 hours 3. Glasgow Coma Scale (GCS) ≥ 13 at the time of initial injury for study enrollment. 4. Post-Concussion Symptom Scale Score minimum of 15 5. Initial provider visit is within 7 days of injury 6. In generally good health as confirmed by medical history and determined by site investigator or designated trained healthcare professional under the supervision of the principal investigator. 7. Has informed consent obtained per protocol and as required per Institutional Review Board Exclusion Criteria: 1. Age \< 13 years or \> 21 years 2. Inability to understand the study requirements or provide informed consent 3. Cleared to return to play during initial visit 4. Prior participation in a Pro2Cool Clinical Study 5. Serious traumatic brain injury as evidenced by worsening symptoms: * Vomiting \> 2 episodes following injury * Seizure * Hospitalization * Radiology scan indicating brain bleed * Slurred speech which has not resolved within 72 hours of concussive injury 6. Physical (e.g., head or neck injury that requires medical treatment) or mental disability hindering adequate response to assessment of symptoms 7. Hemodynamic instability/medical condition requiring further acute life-saving medical intervention 8. History of psychiatric disorder that includes suicide attempts within the last 6 months, unmanaged depression or anxiety, hospitalization for psychiatric treatment within the last 6 months 9. Known brain mass, intracranial hemorrhage, skull fracture 10. Scalp abnormalities including laceration or bleeding 11. Presence of ventriculoperitoneal (VP) shunt 12. Known hematological malignancies, including, but not limited to: multiple myeloma, leukemia, and lymphoma 13. Known history of Reynaud's Disease compromised liver function, cold agglutination, cold sensitivity, cryoglobulinemia, cryofibrinogenemia, and/or a history of severe migraines 14. Known or disclosed pregnancy or breast-feeding 15. Sustains another head or neck injury at the time of concussive injury which requires medical treatment
Contact & Investigator
Brian Reilly, MD
PRINCIPAL INVESTIGATOR
Children's Hospital Medical Center of Akron
Frequently Asked Questions
Who can join the NCT06929923 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 21 Years, studying Concussion, Mild. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06929923 currently recruiting?
Yes, NCT06929923 is actively recruiting participants. Contact the research team at jzak@tectraum.com for enrollment information.
Where is the NCT06929923 trial being conducted?
This trial is being conducted at Ann Arbor, United States, Akron, United States, Cleveland, United States.
Who is sponsoring the NCT06929923 clinical trial?
NCT06929923 is sponsored by TecTraum Inc.. The principal investigator is Brian Reilly, MD at Children's Hospital Medical Center of Akron. The trial plans to enroll 66 participants.